🇪🇺 Eporatio in European Union

EMA authorised Eporatio on 23 October 2009

Marketing authorisations

EMA — authorised 23 October 2009

  • Application: EMEA/H/C/001036
  • Marketing authorisation holder: Teva GmbH
  • Local brand name: Biopoin
  • Indication: Treatment of symptomatic anaemia associated with chronic renal failure in adult patients. Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
  • Status: approved

Read official source →

EMA — authorised 29 October 2009

  • Status: approved

EMA — authorised 29 October 2009

  • Application: EMEA/H/C/001033
  • Marketing authorisation holder: Ratiopharm GmbH
  • Local brand name: Eporatio
  • Indication: Treatment of symptomatic anaemia associated with chronic renal failure in adult patients. Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
  • Status: approved

Read official source →

EMA — authorised 26 April 2010

  • Application: EMEA/H/C/001035
  • Marketing authorisation holder: Ratiopharm GmbH
  • Local brand name: Ratioepo
  • Indication: Treatment of symptomatic anaemia associated with chronic renal failure in adult patients and treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy
  • Status: withdrawn

Read official source →

Eporatio in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Hematology approved in European Union

Frequently asked questions

Is Eporatio approved in European Union?

Yes. EMA authorised it on 23 October 2009; EMA authorised it on 29 October 2009; EMA authorised it on 29 October 2009.

Who is the marketing authorisation holder for Eporatio in European Union?

Teva GmbH holds the EU marketing authorisation.